Design of Improved Antidiabetic Drugs: A Journey from Single to Multitarget Agents
Sign Up to like & getrecommendations! Published in 2022 at "ChemMedChem"
DOI: 10.1002/cmdc.202200320
Abstract: Multifactorial diseases exhibit a complex pathophysiology with several factors contributing to their pathogenesis and development. Examples of such disorders are neurodegenerative (e. g. Alzheimer's, Parkinson's) and cardiovascular diseases (e. g. atherosclerosis, metabolic syndrome, diabetes II). Traditional therapeutic… read more here.
Keywords: multitarget agents; improved antidiabetic; multitarget; antidiabetic drugs ... See more keywords
Meta‐analysed numbers needed to treat of novel antidiabetic drugs for cardiovascular outcomes
Sign Up to like & getrecommendations! Published in 2022 at "ESC Heart Failure"
DOI: 10.1002/ehf2.14213
Abstract: Absolute treatment effects—i.e. numbers needed to treat (NNTs)—of novel antidiabetic drugs for cardiovascular outcomes have not been comprehensively evaluated. We aimed to perform a meta‐analysis of digitalized individual patient outcomes to display and compare absolute… read more here.
Keywords: novel antidiabetic; antidiabetic drugs; numbers needed; drugs cardiovascular ... See more keywords
Cardiovascular Safety of Antidiabetic Drugs in the Hospital Setting
Sign Up to like & getrecommendations! Published in 2017 at "Current Diabetes Reports"
DOI: 10.1007/s11892-017-0884-1
Abstract: Purpose of ReviewPatients with diabetes and/or stress hyperglycemia requires good glycemic control in the hospital setting, often requiring the use of glucose-lowering therapy. Standard-of-care dictates that non-insulin therapy be discontinued, with insulin therapy initiated using… read more here.
Keywords: antidiabetic drugs; safety; insulin therapy; cardiovascular safety ... See more keywords
Effects of antidiabetic drugs on NLRP3 inflammasome activity, with a focus on diabetic kidneys.
Sign Up to like & getrecommendations! Published in 2019 at "Drug discovery today"
DOI: 10.1016/j.drudis.2018.08.005
Abstract: Inflammatory responses have a pivotal role in the development of diabetic nephropathy (DN). The nod-like receptor family, pyrin domain-containing 3 (NLRP3) inflammasome is a newly recognized and potent inflammatory mediator that induces inflammatory responses in… read more here.
Keywords: antidiabetic drugs; drugs nlrp3; inflammasome activity; effects antidiabetic ... See more keywords
Mechanisms of antidiabetic drugs and cholesterol efflux: a clinical perspective.
Sign Up to like & getrecommendations! Published in 2022 at "Drug discovery today"
DOI: 10.1016/j.drudis.2022.02.006
Abstract: Reverse cholesterol transport (RCT) is a physiological process that reduces excess cholesterol in the body. Cholesterol efflux (CE), an important step in RCT, is mainly mediated by ATP-binding cassette transporters A1 and G1 and has… read more here.
Keywords: antidiabetic drugs; efflux clinical; cholesterol; drugs cholesterol ... See more keywords
Antidiabetic drugs and stroke risk. Current evidence.
Sign Up to like & getrecommendations! Published in 2018 at "European journal of internal medicine"
DOI: 10.1016/j.ejim.2017.09.019
Abstract: Cardiovascular disease (CVD) is the major cause of morbidity and mortality for individuals with type 2 diabetes (T2D). In particular, the risk for stroke is twice that of patients without diabetes, and diabetes may be… read more here.
Keywords: antidiabetic drugs; risk; stroke risk; evidence ... See more keywords
Anti-inflammatory properties of antidiabetic drugs: A “promised land” in the COVID-19 era?
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Diabetes and Its Complications"
DOI: 10.1016/j.jdiacomp.2020.107723
Abstract: Inflammation is implicated in the development and severity of the coronavirus disease 2019 (COVID-19), as well as in the pathophysiology of diabetes. Diabetes, especially when uncontrolled, is also recognized as an important risk factor for… read more here.
Keywords: anti inflammatory; antidiabetic drugs; era; properties antidiabetic ... See more keywords
Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: think out of the box!
Sign Up to like & getrecommendations! Published in 2019 at "Metabolism: clinical and experimental"
DOI: 10.1016/j.metabol.2019.154001
Abstract: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in Western societies and a major cause of hepatic disease worldwide. Its more severe type, namely nonalcoholic steatohepatitis (NASH), may result in the… read more here.
Keywords: antidiabetic drugs; fatty liver; effects newer; disease ... See more keywords
Diabetes, antidiabetic medications and risk of depression – A population-based cohort and nested case-control study
Sign Up to like & getrecommendations! Published in 2022 at "Psychoneuroendocrinology"
DOI: 10.1016/j.psyneuen.2022.105715
Abstract: OBJECTIVE Diabetes type 2 is associated with depression, but the impact of antidiabetic drugs is not clear. The objective was to analyze the association between diabetes type 2, antidiabetic drugs, and depression. METHODS This register-based… read more here.
Keywords: antidiabetic drugs; study; patients diabetes; depression ... See more keywords
Institutional Experience With New Antidiabetic Drugs in Kidney Transplant.
Sign Up to like & getrecommendations! Published in 2021 at "Transplantation proceedings"
DOI: 10.1016/j.transproceed.2021.08.042
Abstract: BACKGROUND The recent introduction of new antidiabetic drugs, analogs of glucagon-like peptide-1 (GLP-1) and sodium-glucose cotransporter 2 inhibitors, has shown excellent results in the management of patients with diabetes with chronic kidney disease. However, documented… read more here.
Keywords: antidiabetic drugs; new antidiabetic; kidney transplant; institutional experience ... See more keywords
Sodium-Glucose Cotransporter Inhibitors as Antidiabetic Drugs: Current Development and Future Perspectives
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Medicinal Chemistry"
DOI: 10.1021/acs.jmedchem.2c00867
Abstract: Sodium-glucose cotransporter 2 (SGLT-2) inhibitors (gliflozins) represent the most recently approved class of oral antidiabetic drugs. SGLT-2 overexpression in diabetic patients contributes significantly to hyperglycemia and related complications. Therefore, SGLT-2 became a highly interesting therapeutic… read more here.
Keywords: antidiabetic drugs; sglt; glucose cotransporter; cotransporter inhibitors ... See more keywords